Geode Capital Management LLC Boosts Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Geode Capital Management LLC increased its position in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 6.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 685,989 shares of the company’s stock after buying an additional 40,692 shares during the quarter. Geode Capital Management LLC’s holdings in Werewolf Therapeutics were worth $1,454,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $165,000. Rhumbline Advisers acquired a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $79,000. Acadian Asset Management LLC raised its position in Werewolf Therapeutics by 22.8% in the 2nd quarter. Acadian Asset Management LLC now owns 212,296 shares of the company’s stock valued at $516,000 after purchasing an additional 39,413 shares during the last quarter. American Century Companies Inc. boosted its stake in Werewolf Therapeutics by 50.7% during the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after purchasing an additional 12,656 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Werewolf Therapeutics by 43.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 160,577 shares of the company’s stock worth $392,000 after purchasing an additional 48,952 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Trading Down 7.1 %

NASDAQ:HOWL opened at $1.44 on Friday. Werewolf Therapeutics, Inc. has a 12-month low of $1.38 and a 12-month high of $8.19. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. The stock’s 50 day simple moving average is $1.80 and its 200-day simple moving average is $2.13. The firm has a market cap of $64.17 million, a P/E ratio of -0.94 and a beta of 0.38.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.